NEWS ANALYSIS: Studies into efficacy of hydroxychloroquine resume despite WHO
The renewed push follows criticism of the quality of data in The Lancet study with researchers saying there is ‘huge uncertainty’ about the drug
04 June 2020 - 16:24
London — Scientists are resuming Covid-19 trials of the now world-famous drug hydroxychloroquine, as confusion continues to reign about the anti-malarial hailed by US President Donald Trump as a potential “game-changer” in fighting the coronavirus pandemic.
The renewed research push follows widespread criticism of the quality of data in a study published by The Lancet, an influential medical journal, which found high risks associated with the treatment...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.